Rett syndrome is caused by mutations in the gene MECP2 in ∼80% of affected individuals. We describe a previously unknown MeCP2 isoform. Mutations unique to this isoform and the absence, until now, of identified mutations specific to the previously recognized protein indicate an important role for the newly discovered molecule in the pathogenesis of Rett syndrome.
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Rett syndrome (RTT; OMIM 312750) is characterized by onset, in girls, of a gradual slowing of neurodevelopment in the second half of the first year of life that proceeds towards stagnation by age 4 years, followed by regression and loss of acquired fine motor and communication skills. A pseudostationary period follows during which a picture of preserved ambulation, aberrant communication and stereotypic hand wringing approximates early autism. Regression, however, remains insidiously ongoing and ultimately results in profound mental retardation 1 .
Up to 80% of individuals with RTT have mutations 2, 3 in exons 3 and 4 of the four-exon gene MECP2 (Fig. 1a) 4 encoding the transcriptional repressor MeCP2. In the known transcript of the gene, all four exons are used, the translation start site is in exon 2, and exon 1 and most of exon 2 form the 5′ untranslated region (UTR) 4 . For clarity, we refer to this transcript as MECP2A and its encoded protein as MeCP2A. We sought to identify MECP2 splice variants contributing new coding sequence that might contain mutations in the remaining individuals with RTT. Inspection of the 5′ UTR showed that, whereas exon 2 has a number of in-frame stop codons upstream of the ATG start codon, exon 1 contains an open reading frame across its entire length, including an ATG. Submitting a theoretical construct composed of exons 1, 3 and 4 to the ATGpr program (http://www.hri.co.jp/atgpr/), which predicts the likelihood that an ATG will be an initiation codon based on the significance of its surrounding Kozak nucleotide context, returned a reliability score of 97%, as compared with 64% for MECP2A. A search in EST databases identified eight examples of our theorized transcript, which we named MECP2B (Fig. 1b) , as compared with 14 examples of MECP2A. MECP2B is predicted to encode a new isoform, MeCP2B, with an alternative, longer N terminus determined by exon 1 (see Supplementary Table 1 online).
To confirm that MECP2B is expressed and not merely an artifact of cDNA library preparation, we amplified cDNA by PCR from a variety of tissues using a 5′ primer in exon 1 and a 3′ primer in exon 3 (Fig. 1a) . We obtained two PCR products corresponding in size and sequence to MECP2A and MECP2B in all tissues, including fetal and adult brain and different brain subregions (Fig. 1c) . Results in mouse were similar (Fig. 1c) . We quantified the expression levels of the two transcripts in adult human brain. Expression of MECP2B was ten times higher than that of MECP2A (Fig. 1d) . We studied the subcellular localization of MeCP2B after transfection of 3′ myc-tagged MECP2B into COS-7 cells and found it to be principally in the nucleus (Fig. 1e) .
To determine whether the new coding region is mutated in RTT, we PCR-amplified and sequenced exon 1 and flanking sequences in 19 girls with typical RTT in whom no mutations had been found in the other exons. One affected individual (V1) carries a deletion of 11 bp in exon 1 (Fig. 2) . The deletion occurs within the predicted exon 1 open reading frame of MECP2B and leads to a frame shift that results in a missense amino acid sequence followed by a premature stop codon after amino acid 36. It does not affect the coding sequence of MECP2A. We did not find this sequence change in any of 200 control individuals, including individual V1's parents and brother. To search, in the remaining affected individuals, for additional exon 1 deletions not detectable by our PCR reaction, we carried out multiplex ligationdependent probe amplification (MLPA) 5 In contrast, no mutation specific to the MeCP2A-defining exon 2 has been identified despite the analysis of several hundred individuals with RTT for mutations in this exon (31 publications; most reviewed in ref.
3). These studies did not include exon 1, as it was considered noncoding.
Exon 1 deletions result in absent or truncated MeCP2B protein. However, they also result in shortening of MECP2A's 5′ UTR and could potentially affect its expression. We tested this possibility in individual V1 by carrying out RT-PCR of whole blood, however, and found no diminution of MECP2A expression (Fig. 2c) . In conclusion, mutation data indicate that inactivation of MeCP2B is sufficient to cause RTT, whereas the same cannot so far be said of MeCP2A.
Why was MECP2B not detected in previous expression studies? Northern analyses showed three transcripts, of 1.9, 5 and 10.1 kb, with the differences in size resulting from alternative polyadenylation signal usage 4, [6] [7] [8] (Fig. 1a) . MECP2B differs from MECP2A in lacking the 124-nucleotide exon 2. At the 5-and 10.1-kb positions on the gel, the two transcripts would not be separable. In the 1.9-kb range, published northern blots do show a thick or double band that is likely to correspond to the two transcripts. Likewise, conventional western-blot analysis would not allow resolution of the two MeCP2 isoforms (molecular weight difference <0.9 kDa; Supplementary Figure 2 Deletion mutation in individual V1. V1 is presently 27 years of age. She first smiled at 4 weeks, sat at 11 months and walked at 22 months, at which time she had a vocabulary of 6 words. By 30 months, she had lost all her words and all interest in her parents and surroundings. She developed ritualistic behaviors, including continuous hand-wringing, which continue to the present. Intermittent seizures subsided in late adolescence. (a) Left, sequence of PCR product from genomic DNA using primers X1F and X1R (Fig. 1a) . Note mixed sequence. Middle and right, sequences of clones of individual V1's wild-type (WT) and mutant alleles, respectively. Red box, 11 nucleotides deleted in the mutated allele. (b) Electropherograms of the same cloned wildtype and deleted alleles. (c) PCR on indicated cDNAs using primers HF and HR1 (Fig. 1a,c) . Lanes 1 and 2 (on 2.5% high-resolution agarose gel) are from whole blood from a control and the affected individual, respectively. Lanes 3-8 (on 6% denaturing polyacrylamide) are from control blood (3), affected individual blood (4), control fetal brain (5), control adult brain (6), control testis (7) and control genomic DNA (8) . Note that expression of the affected individual's MECP2A transcript with the 11-bp exon 1 deletion (band of 266 bp) was not diminished as compared to the nondeleted allele (277 bp). The bands of 141 and 152 bp are the deleted and nondeleted MECP2B transcripts, respectively. See Supplementary Methods online for details.
